Our CEO, Dr. Chengcang Charles Wu, will be attending the 16th annual Next Generation Dx Summit (https://www.nextgenerationdx.com)at the Capital Hilton in Washington D.C. where he will have the opportunity to network with other professionals and researchers to discuss important topics surrounding diagnostic advancements. Intact Genomics is a key player and contributor to novel diagnostic technology development, and we look forward to reviewing the innovative products and technologies this event will feature.  

At the SIVB World Congress, Intact Genomics proudly showcased our new and existing products to hundreds of event attendees from around the world. Our Sales Director, Matthew Jones, Business Development Director, Jennifer Gormley, and CEO, Dr. Chengcang Charles Wu, were able to connect with other biotechnology researchers and professionals to discuss collaboration opportunities. We pride ourselves in our ability to innovate and grow as in vitro biology research continues to evolve. Intact Genomics provides a range of superior quality products and services including Recombinase Polymerase Amplification (RPA) optimization enzymes, custom competent cells, DirectPlate® competent cells, and the Quick10™ cloning kit. 

Intact Genomics Exhibited at SIVB World Congress 2024

Intact Genomics (IG®) scientists and collaborators published 3 papers in peer-reviewed journals recently. For further details, click the links below or contact us for inquiries.

“Activation of cryptic biosynthetic gene clusters by fungal artificial chromosomes to produce novel secondary metabolites”. AIMS Microbiol, 2023; 9(4): 757–779. Published online 2023 Dec 18
“The Identification and Heterologous Expression of the Biosynthetic Gene Cluster Encoding the Antibiotic and Anticancer Agent Marinomycin”. Biomolecules, January 16, 2024
“Terpenoid balance in Aspergillus nidulans unveiled byheterologous squalene synthase expression“. ScienceAdvances, February 21, 2024

These papers represent the culmination of relentless dedication, pioneering spirit, and collaborative efforts within our research community. We extend our heartfelt gratitude to all contributors and eagerly anticipate the transformative impact of these discoveries on science and society.

Stay tuned for more exciting developments from IG scientists as we continue to push the boundaries of life sciences exploration.

On November 30 and Dec 1, 2023, Intact Genomics (IG) had the pleasure of hosting high school students from St. Louis County Parkway schools who participate in Spark and Center for Advanced Professional Studies (CAPS) programs.

Jennifer Gormley, Director of Business Development introduced our innovative products and services used by many scientists around the world, Dr. David Brent Halling, Director of Product Development at Intact Genomics, showed students how cutting-edge technology is developed at IG, and Dr. Chengcang Charles Wu, CEO & Co-founder of Intact Genomics, told a story about how he became a world-renowned scientist and dedicated entrepreneur from being a country boy born to a poor family and illiterate parents in a village of Anhui, China.

These bright students asked terrific questions showing they are eager to learn and participate in life sciences. Student Maura Korte said: “I learned a lot about proteins and how important they are in biotechnology. I feel like you usually only hear about DNA in biotechnology so it was fascinating to see that the field is so much bigger than that!” Hayden Steinkuehler said: “It was a very cool experience in seeing what we might want to do in the future.”

Spark! provides high school students with dynamic, immersion-based student learning experiences to ensure students can understand and respond to an ever-changing world. Center for Advanced Professional Studies (CAPS) programs are nationally recognized, innovative high school programs. CAPS is an example of how business, community and public education can partner to produce personalized learning experiences that educate the workforce of tomorrow, especially in high-skill, high-demand jobs. Intact Genomics is proud to do our part in inspiring talented individuals towards careers in STEM to improve the world.

St. Louis, MO. (August 7, 2023) – Intact Genomics (IG®), a leading provider of cutting-edge molecular biology products and services, is proud to announce that it has been granted the prestigious ISO 13485:2016 certification for the design, development, manufacture and distribution of molecular biology products and services, in standard or custom format for both industries and academic institutes.

ISO 13485 is an internationally recognized standard specifically tailored for medical device manufacturers and companies involved in the design, development, production, and distribution of in vitro diagnostic (IVD) kits and reagents. The certification process involves a rigorous evaluation of a company’s quality management system, ensuring that it complies with the stringent requirements set forth by the ISO 13845 standards.

“Receiving the ISO 13485 certification is a significant milestone for Intact Genomics, ” said Dr. Chengcang Charles Wu, CEO of Intact Genomics. ” This milestone reflects the hard work and collective effort of our entire team to uphold the highest quality standards in our industry. With ISO 13485 certification, our customers can have even greater confidence in the reliability and performance of our molecular biology solutions.”

“Our team has worked tirelessly to implement and adhere to the standards set by ISO 13485,” said Dr. David Brent Halling, Leader of Protein Products Development and Laboratories Manager. “Intact Genomics’ certification to this standard proves and demonstrates to the international community that our products are made with strict adherence to traceability and quality control. This achievement reflects our unwavering commitment to delivering reliable and precise products and services for molecular biology research and diagnostics applications. It also showcases our dedication to meeting the needs and expectations of our valued customers and collaborators.”

The ISO 13485 certification further solidifies Intact Genomics’ position as a trusted partner in the molecular biology industry. The company remains committed to ongoing quality improvement initiatives, ensuring that its products and services continue to meet the evolving needs of the scientific community.

About Intact Genomics, Inc.

Established in 2013, Intact Genomics is a worldwide leader in large DNA fragment cloning and metagenomics technologies. The company continuously focuses on genomic technology innovation by applying large DNA fragment cloning related proprietary technologies in metagenomic research to develop new solutions for natural product-enzyme discovery, agricultural research, and environmental protection. Intact Genomics also provides high-quality life science products and services to help scientists explore the genome structure and function of microorganisms, plants, and animal species. We are proud to provide products and services for more than 2,000 laboratories worldwide.

Intact Genomics^® and IG^® are registered trademarks of Intact Genomics, Inc.

Media Contact:

Andrew Robertson
Vice President of Sales & Marketing
Intact Genomics
11840 Westline Industrial Drive, Suite 120
St. Louis, MO 63146
Email: arobertson@intactgenomics.com
Phone: 314-942-3655 ext. 102

Intact Genomics won first place in the USA from Wazoku Crowd Challenge 12091216978 for our scientist’s submission to Corteva Agriscience™ Open Innovation opportunity on Novel solutions for fungal nucleic acid extraction in May 2023. Intact Genomics is the worldwide leader in large DNA fragment extraction, cloning & metagenomic technologies. Our patented Fungal Artificial Chromosome (FAC) technology can capture large DNA fragments up to 300 kb and shuttle them into advanced or engineered fungal hosts for heterologous expression.

Intact Genomics CEO, Dr. Chengcang Charles Wu, gave a contributed talk of “Fungal Artificial Chromosome Pipeline Enables the Discovery of Novel Compounds from Unique Biosynthetic Gene Clusters” at the 2023 ASP Annual Meeting in Rockville, MD. The talk was in the  Fungal Biosynthesis and Chemodiversity session on Monday July 24th, 1:15pm – 3:25pm.

Intact Genomics changed its DNA arch logo to an exciting new “IG with DNA” design in April 2023. Our previous logo was designed by our founders when they started the company in St. Louis, Missouri. They were inspired by the adventure spirit of Gateway Arch and beauty of DNA. However, as we continue to grow, we believe that our new logo captures the essence of our vision for the future. IG^®  and Intact Genomics^®  are registered trademarks granted by the United States Patent and Trademark Office (USPTO) to Intact Genomics, Inc. The new logo features a modern, vibrant and dynamic design that reflects our commitment to innovation and staying current in the ever-changing business landscape. It embodies our company’s values of creativity, connectivity, and integrity, which align with the DNA of Intact Genomics.

At Plant & Animal Genome Conference (PAG) 30, hundreds of attendees visitted us at Booth 124, and talked with our VP of sales, Mr. Andy Robertson, and/or CEO, Dr. Chengcang Charles Wu to learn more about our new products, services and technologies. Intact Genomics provides superior molecular biology research products including agrobacterium competent cells, Quick10™ cloning kit, recombinase polymerase amplification (RPA) optimization enzymes, custom competent cells and custom genomic services to meet your research needs and serve the worldwide plant and animal genome R&D community.
Dr. Wu also presented “A novel DirectPlate®  chemical competent cell technology ” within the workshop, “Development and Application of Genome Engineering and Transgenic Technology to the Agriculture.”

Intact Genomics had two poster presentations of our recent progresses on drug discovery R&D:
P84 – FUNGAL ARTIFICIAL CHROMOSOMES ACTIVATE THE CRYPTIC BIOSYNTHETIC GENE CLUSTER OF STROBILURINS, A POTENT AGRICULTURAL FUNGICIDE WITH HIGH COMPOUND YIELD
Chengcang Charles WU¹, Andrea Stierle², Donald Stierle², Hongyu Chen¹, Peter Korajczyk¹, Rosa Ye¹, Jeremie Ferey¹ and Niel Mondava², (1)INTACT GENOMICS, INC, ST LOUIS, MO, USA, (2)University of Montana, Missoula, MT, USA

P104 – NOVEL BIOACTIVE PRENYLATED PHENOLS DERIVED FROM HETEROLOGOUS EXPRESSION OF A PSEUDOGYMNOASCUS DESTRUCTANS SQUALENE SYNTHASE GENE IN ASPERGILLUS NIDULANS
Dr. Sung Chul Park¹, Dr. Jin Woo Bok¹, Rosa Ye², Raveena Gupta³, Matthew Robey⁴, Dr. Chengcang Charles Wu², Prof. Neil Kelleher⁴ and Prof. Nancy P. Keller¹, (1)University of Wisconsin-Madison, Madison, WI, USA, (2)INTACT GENOMICS, INC, ST LOUIS, MO, USA, (3)Northwestern University, USA, (4)Northwestern University, Evanston, IL, USA